Modulation of the monocyte/macrophage system in heart failure by targeting heme oxygenase-1.
Animals
Cardiovascular Agents
/ pharmacology
Gene Expression Regulation, Enzymologic
/ drug effects
Genetic Therapy
/ methods
Heart Failure
/ enzymology
Heme Oxygenase-1
/ genetics
Humans
Inflammation Mediators
/ metabolism
Macrophages
/ drug effects
Molecular Targeted Therapy
Monocytes
/ drug effects
Myocardium
/ enzymology
Necrosis
Oxidative Stress
/ drug effects
Signal Transduction
/ drug effects
Cardiac ischemia
Heme oxygenase-1
Immunomodulation
Inflammation
Macrophage
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
19
03
2018
revised:
26
08
2018
accepted:
29
08
2018
pubmed:
15
9
2018
medline:
10
4
2019
entrez:
15
9
2018
Statut:
ppublish
Résumé
Upon myocardial infarction (MI) immune system becomes activated by extensive necrosis of cardiomyocytes releasing intracellular molecules called damage-associated molecular patterns. Overactive and prolonged immune responses are likely to be responsible for heart failure development and progression in patients surviving the ischemic episode. Heme oxygenase-1 (HO-1) plays a crucial role in heme degradation and in this way releases carbon monoxide, free iron, and biliverdin. This stress-inducible enzyme is induced by various oxidative and inflammatory signals. Consequently, biological actions of HO-1 are not limited to degradation of a toxic heme released from hemoproteins, but also provide an adaptive cellular response against chronic inflammation and oxidative injury. Indeed, the immunomodulatory and anti-inflammatory properties of HO-1 were demonstrated in several experimental studies, as well as in human cases of genetic HO-1 deficiency. HO-1 was shown to suppress the production, myocardial infiltration and inflammatory properties of monocytes and macrophages what resulted in limitation of post-MI cardiac damage. This review specifically addresses the role of HO-1, heme and its degradation products in macrophage biology and post-ischemic cardiac repair. A more complete understanding of these mechanisms is essential to develop new therapeutic approaches.
Identifiants
pubmed: 30213580
pii: S1537-1891(18)30115-0
doi: 10.1016/j.vph.2018.08.011
pii:
doi:
Substances chimiques
Cardiovascular Agents
0
Inflammation Mediators
0
HMOX1 protein, human
EC 1.14.14.18
Heme Oxygenase-1
EC 1.14.14.18
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-90Informations de copyright
Copyright © 2018. Published by Elsevier Inc.